ボルテゾミブ療法におけるアゾール系抗真菌薬併用時の有害事象調査
スポンサーリンク
概要
- 論文の詳細を見る
The main metabolic pathway of bortezomib is related to cytochrome P450 (CYP) 3A4. Azole-based antifungal agents are typical CYP3A4 inhibitors and frequently administered for hematological diseases as prophylaxis or treatment. It is important to evaluate the clinical impacts of drug interactions between bortezomib and azole-based antifungal agents, with the view of providing better treatment. In this study, we investigated in 73 patients, who received bortezomib therapy, for the occurrence of adverse events such as hematotoxicity and peripheral neuropathy: combination with an azole-based antifungal group (n = 22) and bortezomib alone group (n = 51). The incidence of Grade 3/4 leukopenia and sensory peripheral neuropathy in the combination group was increased significantly compared to the bortezomib group (45.5% > 17.6%, 27.3% > 3.9%, respectively; both P < 0.05). Leukopenia was observed in the combination group gradually after adding an azole antifungal. The decrease ratio was significantly higher in patients with voriconazole or itraconazole, and the days to nadir were shorter in patients with voriconazole or itraconazole (median 11 days; P < 0.01). The number of patients with progression of sensory peripheral neuropathic was similar in both groups; however, the days to exacerbation were shorter in patients with voriconazole or itraconazole (median 14.5 days; P < 0.05). Concomitant use of azole-based antifungal agents might exacerbate bortezomib-induced adverse events (i.e. leukopenia and sensory peripheral neuropathy); therefore, health care professionals should closely monitor adverse events when bortezomib is administered with azole-based antifungal agents.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)